Spots Global Cancer Trial Database for HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Official Title: HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Study ID: NCT04618367

Conditions

Carcinoma, Hepatocellular

Liver Neoplasms

Sintilimab

Portal Vein Tumor Thrombus

Interventions

Hepatic arterial infusion chemotherapy

Lenvatinib

Sintilimab

Study Description

Brief Summary: This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.

Detailed Description: Hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin was effective and safe for hepatocellular carcinoma. Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma, and Sintilimab, an programmed cell death protein-1 (PD-1) antibody, was effective and tolerable in patients with hepatocellular carcinoma and portal vein tumor thrombus. No study has evaluated HAIC plus Lenvatinib and Sintilimab. Thus, the investigators carried out this prospective, single-arm study to find out it.